trending Market Intelligence /marketintelligence/en/news-insights/trending/1bbmqssgerhbkbktkcb_aq2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Neon Therapeutics to use Natera's DNA test in lung cancer study

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Neon Therapeutics to use Natera's DNA test in lung cancer study

Cambridge, Mass.-based Neon Therapeutics Inc. will use Natera Inc.'s custom DNA test to measure treatment response in a lung cancer study of its NEO-PV-01 drug.

Natera's Signatera is a circulating tumor DNA assay designed to monitor treatment response, detect remaining cancer cells and predict disease recurrence.

NEO-PV-01 is Neon Therapeutics' personal cancer vaccine designed specifically for each patient and their tumor-specific DNA mutations.

Neon Therapeutics, in collaboration with Merck & Co. Inc., is conducting an early stage trial, known as NT-002, to evaluate the safety and effectiveness of NEO-PV-01 in combination with Merck's blockbuster drug Keytruda and chemotherapy for untreated patients with advanced or non-squamous non-small cell lung cancer that has spread into other parts of the body.

With the help of Signatera, the companies aim to assess the immunological and clinical treatment response of patients with more specificity and sensitivity.

In September, Bristol-Myers Squibb Co. also agreed to use Signatera in a phase 2 study testing Opdivo, a rival of Keytruda, as an additional therapy for patients with lung cancer.

San Carlos, Calif.-based Natera is a genetic testing and diagnostics company that develops noninvasive methods for analyzing DNA.

SNL Image